PROCEPT BioRobotics Corporation Sales-type Lease, Revenue
PROCEPT BioRobotics Corporation (PRCT) reported Sales-type Lease, Revenue of $504.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SalesTypeLeaseRevenue · last filed 2026-08-05
- PROCEPT BioRobotics Corporation sales-type lease, revenue for the quarter ending 2026-06-30 was $504.00K, a 58.45% decline year-over-year.
- PROCEPT BioRobotics Corporation sales-type lease, revenue for the quarter ending 2026-03-31 was $0.00.
- PROCEPT BioRobotics Corporation sales-type lease, revenue for the quarter ending 2025-12-31 was $839.00K, a 38.17% decline year-over-year.
- PROCEPT BioRobotics Corporation sales-type lease, revenue for the quarter ending 2025-09-30 was $957.00K.
- PROCEPT BioRobotics Corporation sales-type lease, revenue for fiscal 2025 was $3.02M, a 122.33% increase from fiscal 2024.
- PROCEPT BioRobotics Corporation sales-type lease, revenue for fiscal 2024 was $1.36M, a 225.42% increase from fiscal 2023.
- PROCEPT BioRobotics Corporation sales-type lease, revenue for fiscal 2023 was $417.00K.
- PROCEPT BioRobotics Corporation sales-type lease, revenue for fiscal 2022 was $0.00.
| Period end | Sales-type Lease, Revenue 3 month | Sales-type Lease, Revenue 6 month | Sales-type Lease, Revenue 9 month | Sales-type Lease, Revenue 12 month |
|---|---|---|---|---|
| 2026-06-30 | $504.00K 10-Q · filed 2026-08-05 | $504.00K 10-Q · filed 2026-08-05 | $1.34M derived: sum of 3 quarters · filed 2026-08-05 | $2.30M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $0.00 10-Q · filed 2026-04-30 | $839.00K derived: sum of 2 quarters · filed 2026-04-30 | $1.80M derived: sum of 3 quarters · filed 2026-04-30 | $3.01M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $839.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $1.80M derived: sum of 2 quarters · filed 2026-02-26 | $3.01M derived: sum of 3 quarters · filed 2026-08-05 | $3.02M 10-K · filed 2026-02-26 |
| 2025-09-30 | $957.00K 10-Q · filed 2025-11-05 | $2.17M derived: sum of 2 quarters · filed 2026-08-05 | $2.18M 10-Q · filed 2025-11-05 | $3.53M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $1.21M 10-Q · filed 2026-08-05 | $1.21M 10-Q · filed 2026-08-05 | $2.57M derived: sum of 3 quarters · filed 2026-08-05 | $2.57M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $0.00 10-Q · filed 2026-04-30 | $1.36M derived: sum of 2 quarters · filed 2026-04-30 | $1.36M derived: sum of 3 quarters · filed 2026-04-30 | $1.36M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $1.36M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $1.36M derived: sum of 2 quarters · filed 2026-02-26 | $1.36M derived: sum of 3 quarters · filed 2026-02-26 | $1.36M 10-K · filed 2026-02-26 |
| 2024-09-30 | $0.00 10-Q · filed 2025-11-05 | $0.00 derived: sum of 2 quarters · filed 2025-11-05 | $0.00 10-Q · filed 2025-11-05 | |
| 2024-06-30 | $0.00 10-Q · filed 2025-08-07 | $0.00 10-Q · filed 2025-08-07 | ||
| 2024-03-31 | $0.00 10-Q · filed 2025-05-02 | |||
| 2023-12-31 | $417.00K 10-K · filed 2026-02-26 | |||
| 2022-12-31 | $0.00 10-K · filed 2025-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Beta Bionics, Inc. (BBNX) | United States | $0.979B | -9.66 |
| TANDEM DIABETES CARE INC (TNDM) | United States | $1.059B | -16.57 |
| SpyGlass Pharma, Inc. (SGP) | United States | $0.925B | |
| IRADIMED CORP (IRMD) | United States | $1.089B | 52.92 |
| ARTIVION, INC. (AORT) | United States | $1.123B | -345.09 |
| SI-BONE, Inc. (SIBN) | United States | $0.830B | -49.82 |
| INTEGRA LIFESCIENCES HOLDINGS CORP (IART) | United States | $1.234B | -193.02 |
| MIMEDX GROUP, INC. (MDXG) | United States | $0.687B | 89.92 |
| ANGIODYNAMICS INC (ANGO) | United States | $0.632B | -13.02 |
| ORTHOPEDIATRICS CORP (KIDS) | United States | $0.592B |